Literature DB >> 8976661

Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone.

I J Cohen1, L Kornreich, S Mekhmandarov, K Katz, R Zaizov.   

Abstract

In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics. The demonstration of subperiosteal oedema on magnetic resonance imaging (MRI) led to an attempt to use steroids to relieve the oedema and thereby the pain. On eight occasions, five patients with documented bone crises received conventional dose steroids (20 mg/m2/day) with considerable shortening of the attacks. On six occasions five further patients received high dose methylprednisolone (30 mg/kg intravenously or 1 g/m2 orally daily for two days), which was followed by oral prednisone for three to five days on the last four occasions. In this later group, pain relief was evident within several hours. Three treatments were given on an ambulatory basis. The MRI scan of one of these patients showed no subperiosteal fluid collection five days after high dose steroids had been started, and on subsequent x ray examination, there was no periosteal elevation. This treatment should be considered in cases of Gaucher's disease with bone crises.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8976661      PMCID: PMC1511695          DOI: 10.1136/adc.75.3.218

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  22 in total

Review 1.  Bone crisis in Gaucher disease--an update.

Authors:  Z Yosipovitch; K Katz
Journal:  Isr J Med Sci       Date:  1990-10

Review 2.  Effects of cytokines on vascular endothelium: their role in vascular and immune injury.

Authors:  R S Cotran; J S Pober
Journal:  Kidney Int       Date:  1989-04       Impact factor: 10.612

3.  Hemorrhage associated with "bone crisis" in Gaucher's disease identified by magnetic resonance imaging.

Authors:  G Horev; L Kornreich; H Hadar; K Katz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 4.  Cardiovascular collapse after high dose methylprednisolone.

Authors:  I J Cohen
Journal:  Pediatr Hematol Oncol       Date:  1993 Jul-Sep       Impact factor: 1.969

Review 5.  Interleukin-2 toxicity.

Authors:  J P Siegel; R K Puri
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

6.  In vivo dynamics of murine tumor necrosis factor-alpha gene expression. Kinetics of dexamethasone-induced suppression.

Authors:  D G Remick; R M Strieter; J P Lynch; D Nguyen; M Eskandari; S L Kunkel
Journal:  Lab Invest       Date:  1989-06       Impact factor: 5.662

7.  Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease.

Authors:  K Katz; S Mechlis-Frish; I J Cohen; G Horev; R Zaizov; E Lubin
Journal:  J Bone Joint Surg Am       Date:  1991-04       Impact factor: 5.284

8.  Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.

Authors:  G M Pastores; A R Sibille; G A Grabowski
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

Review 9.  Gaucher disease: a heterogeneous clinical complex for which effective enzyme replacement has come of age.

Authors:  E P Frenkel
Journal:  Am J Med Sci       Date:  1993-05       Impact factor: 2.378

10.  Long-term follow-up of partial splenectomy in Gaucher's disease.

Authors:  I J Cohen; K Katz; E Freud; M Zer; R Zaizov
Journal:  Am J Surg       Date:  1992-10       Impact factor: 2.565

View more
  7 in total

Review 1.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

Review 2.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 4.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

Review 5.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 6.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 7.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.